Eledon Pharmaceuticals
ELDN
160 hedge funds and large institutions have $185M invested in Eledon Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 62 increasing their positions, 22 reducing their positions, and 9 closing their positions.
456% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 9
182% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 22
41% more capital invested
Capital invested by funds: $131M → $185M (+$53.3M)
32% more funds holding
Funds holding: 121 → 160 (+39)
4.52% more ownership
Funds ownership: 56.19% → 60.71% (+4.5%)
82% less call options, than puts
Call options by funds: $940K | Put options by funds: $5.28M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$7.78M |
| 2 |
Millennium Management
New York
|
+$3.56M |
| 3 |
BlackRock
New York
|
+$2.7M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.82M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
-$3.37M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
-$3.1M |
| 3 |
S
Sanofi
Paris,
France
|
-$2.51M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.11M |
| 5 |
SG Americas Securities
New York
|
-$1.96M |
ELDN Hedge Fund Activity: Q2 2026 in Review
160 institutional investors reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2026, worth a combined $185M — up 41% from $131M a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new ELDN positions and 9 closed out — a net gain of 41 holders — while 62 added to existing stakes and 22 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $7.78M. The largest seller was Jefferies Financial Group, exiting entirely with an estimated $3.37M sold.
- 160 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2026, up from 121 in Q1 2026.
- Funds reported $185M of Eledon Pharmaceuticals stock for Q2 2026, up 41% quarter-over-quarter.
- 50 funds opened new Eledon Pharmaceuticals positions in Q2 2026 and 9 closed out, a net change of +41 holders.
- The largest Eledon Pharmaceuticals buyer in Q2 2026 was Goldman Sachs, an estimated $7.78M added.
- The largest Eledon Pharmaceuticals seller in Q2 2026 was Jefferies Financial Group, an estimated $3.37M sold.
Based on aggregated 13F filings for Q2 2026.